Armor Investment Advisors LLC Decreases Stake in Johnson & Johnson (NYSE:JNJ)

Armor Investment Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 9.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,359 shares of the company’s stock after selling 1,068 shares during the quarter. Johnson & Johnson comprises 1.3% of Armor Investment Advisors LLC’s holdings, making the stock its 26th largest holding. Armor Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of JNJ. Norges Bank bought a new stake in Johnson & Johnson during the fourth quarter worth $3,220,322,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Johnson & Johnson during the fourth quarter worth $277,294,000. Korea Investment CORP grew its holdings in Johnson & Johnson by 38.9% during the first quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock worth $265,296,000 after buying an additional 596,134 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in Johnson & Johnson by 267.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 533,201 shares of the company’s stock worth $61,435,000 after buying an additional 388,050 shares in the last quarter. Finally, Macquarie Group Ltd. grew its holdings in Johnson & Johnson by 5.6% during the fourth quarter. Macquarie Group Ltd. now owns 6,851,198 shares of the company’s stock worth $789,328,000 after buying an additional 362,616 shares in the last quarter. 66.00% of the stock is currently owned by institutional investors.

In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

Shares of Johnson & Johnson (JNJ) opened at 134.45 on Friday. The firm’s 50-day moving average price is $132.62 and its 200-day moving average price is $129.18. The stock has a market capitalization of $360.86 billion, a P/E ratio of 22.75 and a beta of 0.79. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. During the same quarter in the previous year, the firm posted $1.74 earnings per share. The company’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were given a $0.84 dividend. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.50%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

A number of research analysts have recently commented on JNJ shares. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $138.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 12th. BMO Capital Markets restated a “buy” rating and set a $132.00 price target on shares of Johnson & Johnson in a research report on Friday, June 2nd. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target on the stock in a research report on Monday, May 29th. BidaskClub lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Finally, UBS AG reiterated a “buy” rating and issued a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus price target of $134.60.

COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/17/armor-investment-advisors-llc-lowers-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply